Member Info for Laura2022

Thanks Badsterman for the link

Apologies

Loss will be about £5mln for GDR when full year results are released in November

This was from most recent half year, YET porky boldly claims a 50p target and £10-20mln revenues will miraculously appear

If calrsberg did ramps

FINANCIAL HIGHLIGHTS

 

· Revenue and other income of £0.24m (H1 2022/3: £0.02m)

· R&D spend of £1.9m (H1 2022/3: £2.0m)

· Operating loss of £2.4m (H1 2022/3: £2.7

We'll leave the ramps to professionals like you

GDR lost £3.8mln most years and last years full revenues were about £500k or less, but yet you boldly claimed ....

Porky9

Posted in: GDR

Posts: 7,144

Price: 2.475

No Opinion

RE: NHS now promoting the use of the Genedrive machines13 Oct 2024 08:28

Saving the NHS £160m a year with nationwide roll out not to mention significantly improving patient lives, what is not to like.

And that is before we even consider the US and global markets.

This is a £250m company in the making, 50p SP Target

Porks

How can you state rampers when on GDR last week you were claiming a value of £250mln /50p

Despite GDR.only previously having made about £500k in revenue?

He claims he doesn't know porky *or nick'

But has frequently mentioned them

Eg

Grainger14

Posted in: VAL

Posts: 110

Price: 4.35

No Opinion

Valirx26 Feb 2024 12:38

Hi...

Why do posters hound the only 2 posters who got it right..

Nick and Porky read this right and if only people had listern to them we would be in a far better state than we are now.

Rampers and the BOD have got us in this mess.

Stop the BS and face the FACTS untill we have a change of leadership we are going down and out. Over to the rampers now to have a go at me.

Just my opinion.

All this hatred for £900 !!!

Grainger14

Posted in: VAL

Posts: 110

Price: 4.95

No Opinion

Truth2 Feb 2024 18:50

My name is Neil Grainger

I have £900 invested in valirx..

I have no reason to lie.

Lets here who you are...???

Those who protesteth most

Out of all the shares that are fraudulent you mention DDDD

Strange you mention DDDD

Porky was in that too

Grainger

You must have bene really burned to be as bitter as you are

What happened to you and VAL ?

Be honest

Your history says you actually have no actual investments

UPL WJG OBD WBI

Pathetic way to live

Filtered

Sham

1) there's been only 1 holding RNS and that was simply to trim

2) why do you just go from board to board like an ambulance chaser ?

3) what are YOU invested in?

Top institutional shareholdings

% holding

Vulpes Investment Management 9.51

Arbuthnot Latham (Nominees)* 9.13

Unicorn Asset Management 8.06

Lombard Odier Asset Management 4.99

Seneca Partners* 4.93

Investec Wealth & Investment* 4.99

Top investors 41.61

Other shareholders 58.39

Total shareholders 100.00

Source: Oxford BioDynamics Note: as of 15/10/24 * as last notified to Oxford BioDynamics

Bunsen

The charts are now very oversold , the broker note says cash until early 2025 ( = time to find solution) and top side valuation of 52p ..so even a 1/10th of that isb5p

Also OBD said they're in talks WITH USA partners

Taken from a new broker note on OBD

he prostate cancer market is large, with an estimated c 299k new cases in the US in 2024, and around 25m PSA tests performed each year in the US alone (and likely similar again in rest-of-world). We assume that EpiSwitch PSE can capture 1% of this market, implying 250k tests per annum. This would also be possible to achieve within existing facilities, with current capacity for 50k tests per quarter, which could be increased substantially through the addition of extra shifts. Hence 250k tests per annum seems achievable in the context of both the market opportunity and capacity, but will require continued spend on commercialisation. We assume peak testing volumes could be reached within the next 10 years.

Global sales of CPIs are around $40bn, with Merck’s Keytruda (pembrolizumab, a PD-1 inhibitor) accounting for $25bn sales in 2023 ($15bn in the US). Based on Keytruda’s $11k list price (three-weekly dose) in the US, and applying Merck’s reported average 37% gross:net discount (across Merck’s entire US pharma portfolio), this suggests >1m doses of Keytruda were prescribed in the US in 2023, for perhaps 200-300k patients, assuming between 4-6 doses per patient

They don't need to issue now

If they had /have any left it went

Let's see after 4pm trades show

Off topic huge upside OBD

1.1p with potential for 52p

I'll take that chances

Oxford BioDynamics is leading the way in 3D genomic diagnostics, developing innovative and clinically robust tests using its proprietary EpiSwitch platform. EpiSwitch CiRT (Checkpoint Inhibitor Response Test), predicts a patient’s response to cancer immunotherapy, and the PROWES registry study is underway to generate uptake and to support inclusion in key guidelines. EpiSwitch PSE, for prostate cancer, has recently been launched and is initially targeting the concierge medicine sector in the US. Growing testing volumes will require ongoing commercial investment. Our DCF-based valuation of £162m ($203m), or 52p/share assumes OBD can successfully navigate the Q125 cash shortfall, and deliver on the sales potential of these tests.

The answers reassured me that the directors are planning for 2025 and beyond and therefore see a viable business contrary to some of the points made here

They clarified the net/gross payment in shares and that there was no immediate need for funding and pointed me to the RNS working regarding Q1 2025

From the company to 3 question i put to them

I am happy with the responses but legally I cannot share sorry

Absolutely NU

Some of the comments today from others are appalling